Systematic risk in the biopharmaceutical sector: A multiscale approach

Gazi Salah Uddin, Muhammad Yahya* (Corresponding Author), Stelios Bekiros, Ranadeva Jayasekera, Gerhard Kling

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

It is well documented that the biopharmaceutical sector has exhibited weak financial returns, contributing to underinvestment. Innovations in the industry carry high risks; however, an analysis of systematic risk and return compared to other asset classes is missing. This paper investigates the time-frequency interconnectedness between stocks in the biotech sector and ten asset classes using daily cross-country data from 1995 to 2019. We capture investors' heterogeneous investment horizons by decomposing time series according to frequencies. Using a maximal overlap discrete wavelet transform (MODWT)
and a dynamic conditional correlation (DCC)-Student-t copula, diversification potentials are revealed, helping investors to reap the benefits of investing in biotech. Our findings indicate that the underlying assets exhibit nonlinear asymmetric behavior that strengthens during periods of turmoil.
Original languageEnglish
JournalAnnals Of Operations Research
Publication statusAccepted/In press - 30 Oct 2021

Keywords

  • OR in medicine
  • biotech
  • time-varying copulas
  • wavelets
  • risk management

Fingerprint

Dive into the research topics of 'Systematic risk in the biopharmaceutical sector: A multiscale approach'. Together they form a unique fingerprint.

Cite this